Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral chidamide in relapsed or refractory cutaneous T-cell lymphoma
ChiCTR-TNC-10000806Phase 2Completed
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Response rate. Started Mar 2009; status: completed.
02
Drugs
tucidinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on ChiCTR-TNC-10000806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10000806.